Temple University cherry "T" logo

School or College Name

Search Keywords

Douglas Tilley

Profile Picture of Douglas Tilley

Douglas Tilley

  • Lewis Katz School of Medicine

    • Center for Translational Medicine

      • Associate Professor

Biography

Doug received his PhD in 2005 from the Department of Pharmacology and Toxicology at Queen's University at Kingston, ON, Canada, where he worked with Dr. Donald Maurice on the role of phosphodiesterase types 3 and 4 in the phenotypic regulation of vascular smooth muscle cells. Subsequently, he completed postdoctoral work in the laboratory of Dr. Howard Rockman in Cardiology at Duke University, Durham, NC, exploring the molecular mechanisms by which β-adrenergic receptors (βARs) associate with and transactivate epidermal growth factor receptor. Doug initially established his independent laboratory at Thomas Jefferson School of Pharmacy in Philadelphia, PA in 2008, then moved across town in 2012 to the Center for Translational Medicine at the Lewis Katz School of Medicine, Temple University. Research in his lab continues to focus upon the impact of novel G protein-coupled receptor-dependent signaling pathways on cardiac function and response to stress, and whether they can be differentially engaged in a pathway- and cell type-specific manner to improve outcomes in response to acute cardiac injury or chronic heart failure.

Google Scholar: Douglas Tilley

Labs: Douglas Tilley

Research Interests

  • G protein-coupled receptors
  • Heart failure
  • Cell signaling
  • Molecular pharmacology
  • Epidermal growth factor receptor

Selected Publications

Recent

  • Okyere, A. & Tilley, D. (2021). Self-made allostery: endogenous COMP antagonizes pathologic AT1AR signaling. Cell Research, 31(7), 730-731. doi: 10.1038/s41422-021-00493-x.

  • Okyere, A., McEachern, E., Strong, J., Teplitsky, D., Issiako, F., Carter, R., Gao, E., & Tilley, D. (2021). Myeloid Cell‐Specific Epidermal Growth Factor Receptor (EGFR) Regulates the Immune Response in the Infarcted Heart. The FASEB Journal, 35(S1). doi: 10.1096/fasebj.2021.35.s1.05249.

  • Guo, S., Okyere, A.D., McEachern, E., Strong, J.L., Carter, R.L., Patwa, V.C., Thomas, T.P., Landy, M., Song, J., Lucchese, A.M., Martin, T.G., Gao, E., Rajan, S., Kirk, J.A., Koch, W.J., Cheung, J.Y., & Tilley, D.G. (2021). Epidermal growth factor receptor-dependent maintenance of cardiac contractility. Cardiovascular Research. doi: 10.1093/cvr/cvab149.

  • Lucia, C.d., Grisanti, L.A., Borghetti, G., Piedepalumbo, M., Ibetti, J., Lucchese, A.M., Barr, E.W., Roy, R., Okyere, A.D., Murphy, H.C., Gao, E., Rengo, G., Houser, S.R., Tilley, D.G., & Koch, W.J. (2021). GRK5 contributes to impaired cardiac function and immune cell recruitment in post-ischemic heart failure. Cardiovascular Research, cvab044-. doi: 10.1093/cvr/cvab044.

  • Patwa, V., Guo, S., Carter, R., Kraus, L., Einspahr, J., Teplitsky, D., Sabri, A., & Tilley, D. (2021). Epidermal growth factor receptor association with β1-adrenergic receptor is mediated via its juxtamembrane domain. Cellular Signalling, 78. doi: 10.1016/j.cellsig.2020.109846.

  • Nayak, T. & Tilley, D. (2021). Recent advances in GPCR-regulated leukocyte responses during acute cardiac injury. Current Opinion in Physiology, 19, 55-61. doi: 10.1016/j.cophys.2020.09.007.

  • Lieu, M., Traynha, C., Lucia, C.D., Pfleger, J., Piedepalumbo, M., Roy, R., Petovic, J., Landesberg, G., Forreste, S., Hoffman, M., Grisant, L., Yuan, A., Gao, E., Drosatos, K., Eguchi, S., Scalia, R., Tille, D., & Koc, W. (2020). Loss of dynamic regulation of G protein-coupled receptor kinase 2 by nitric oxide leads to cardiovascular dysfunction with aging. American Journal of Physiology - Heart and Circulatory Physiology, 318(5), H1162-H1175. doi: 10.1152/ajpheart.00094.2020.

  • Okyere, A. & Tilley, D. (2020). Leukocyte-Dependent Regulation of Cardiac Fibrosis. Frontiers in Physiology, 11. doi: 10.3389/fphys.2020.00301.

  • Vemulapalli, H., Albayati, S., Patwa, V., Tilley, D., Tsygankov, A., & Liverani, E. (2020). ADP exerts P2Y12 -dependent and P2Y12 -independent effects on primary human T cell responses to stimulation. Journal of Cell Communication and Signaling, 14(1), 111-126. doi: 10.1007/s12079-019-00540-8.

  • Ahmad, F., Tomar, D., C, S.A.A., Elmoselhi, A., Thomas, M., Elrod, J., Tilley, D., & Force, T. (2020). Nicotinamide riboside kinase-2 alleviates ischemia-induced heart failure through P38 signaling. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1866(3). doi: 10.1016/j.bbadis.2019.165609.

  • Guo, X., Kolpakov, M., Hooshdaran, B., Schappell, W., Wang, T., Eguchi, S., Elliott, K., Tilley, D., Rao, A., Andrade-Gordon, P., Bunce, M., Madhu, C., Houser, S., & Sabri, A. (2020). Cardiac Expression of Factor X Mediates Cardiac Hypertrophy and Fibrosis in Pressure Overload. JACC: Basic to Translational Science, 5(1), 69-83. doi: 10.1016/j.jacbts.2019.10.006.

  • Kolpakov, M., Guo, X., Rafiq, K., Vlasenko, L., Hooshdaran, B., Seqqat, R., Wang, T., Fan, X., Tilley, D., Kostyak, J., Kunapuli, S., Houser, S., & Sabri, A. (2020). Loss of Protease-Activated Receptor 4 Prevents Inflammation Resolution and Predisposes the Heart to Cardiac Rupture after Myocardial Infarction. Circulation, 758-775. doi: 10.1161/CIRCULATIONAHA.119.044340.

  • Scholpa, N., Simmons, E., Tilley, D., & Schnellmann, R. (2019). β2-adrenergic receptor-mediated mitochondrial biogenesis improves skeletal muscle recovery following spinal cord injury. Experimental Neurology, 322. doi: 10.1016/j.expneurol.2019.113064.

  • Burczyk, M., Burkhalter, M., Tena, T., Grisanti, L., Kauk, M., Matysik, S., Donow, C., Kustermann, M., Rothe, M., Cui, Y., Raad, F., Laue, S., Moretti, A., Zimmermann, W., Wess, J., Köhl, M., Hoffmann, C., Tilley, D., & Philipp, M. (2019). Muscarinic receptors promote pacemaker fate at the expense of secondary conduction system tissue in zebrafish. JCI Insight, 4(20). doi: 10.1172/jci.insight.121971.

  • Ahmad, F., Singh, A., Tomar, D., Rahmani, M., Zhang, Q., Woodgett, J., Tilley, D., Lal, H., & Force, T. (2019). Cardiomyocyte-GSK-3α promotes mPTP opening and heart failure in mice with chronic pressure overload. Journal of Molecular and Cellular Cardiology, 130, 65-75. doi: 10.1016/j.yjmcc.2019.03.020.

  • Grisanti, L., Lucia, C.D., Thomas, T., Stark, A., Strony, J., Myers, V., Beretta, R., Yu, D., Sardu, C., Marfella, R., Gao, E., Houser, S., Koch, W., Hamad, E., & Tilley, D. (2019). Prior beta blocker treatment decreases leukocyte responsiveness to injury. JCI Insight, 4(9). doi: 10.1172/jci.insight.99485.

  • Sato, P., Chuprun, J.K., Grisanti, L., Woodall, M., Brown, B., Roy, R., Traynham, C., Ibetti, J., Lucchese, A., Yuan, A., Drosatos, K., Tilley, D., Gao, E., & Koch, W. (2018). Restricting mitochondrial GRK2 post-ischemia confers cardioprotection by reducing myocyte death and maintaining glucose oxidation. Science Signaling, 11(560). doi: 10.1126/scisignal.aau0144.

  • Bajpai, A. & Tilley, D. (2018). The role of leukocytes in diabetic cardiomyopathy. Frontiers in Physiology, 9(NOV). doi: 10.3389/fphys.2018.01547.

  • Pfleger, J., Gross, P., Johnson, J., Carter, R., Gao, E., Tilley, D., Houser, S., & Koch, W. (2018). G protein-coupled receptor kinase 2 contributes to impaired fatty acid metabolism in the failing heart. Journal of Molecular and Cellular Cardiology, 123, 108-117. doi: 10.1016/j.yjmcc.2018.08.025.

  • Myers, V., Gerhard, G., McNamara, D., Tomar, D., Madesh, M., Kaniper, S., Ramsey, F., Fisher, S., Ingersoll, R., Kasch-Semenza, L., Wang, J., Hanley-Yanez, K., Lemster, B., Schwisow, J., Ambardekar, A., Degann, S., Bristow, M., Sheppard, R., Alexis, J., Tilley, D., Kontos, C., McClung, J., Taylor, A., Yancy, C., Khalili, K., Seidman, J., Seidman, C., McTiernan, C., Cheung, J., & Feldman, A. (2018). Association of Variants in BAG3 with Cardiomyopathy Outcomes in African American Individuals. JAMA Cardiology, 3(10), 929-938. doi: 10.1001/jamacardio.2018.2541.

  • Grisanti, L., Schumacher, S., Tilley, D., & Koch, W. (2018). Designer Approaches for G Protein–Coupled Receptor Modulation for Cardiovascular Disease. JACC: Basic to Translational Science, 3(4), 550-562. doi: 10.1016/j.jacbts.2017.12.002.

  • Grisanti, L., Thomas, T., Carter, R., Lucia, C.d., Gao, E., Koch, W., Benovic, J., & Tilley, D. (2018). Pepducin-mediated cardioprotection via β-arrestin-biased β2-adrenergic receptor-specific signaling. Theranostics, 8(17), 4664-4678. doi: 10.7150/thno.26619.

  • Hooshdaran, B., Kolpakov, M., Guo, X., Miller, S., Wang, T., Tilley, D., Rafiq, K., & Sabri, A. (2017). Dual inhibition of cathepsin G and chymase reduces myocyte death and improves cardiac remodeling after myocardial ischemia reperfusion injury. Basic Research in Cardiology, 112(6). doi: 10.1007/s00395-017-0652-z.

  • Guo, S., Carter, R., Grisanti, L., Koch, W., & Tilley, D. (2017). Impact of paroxetine on proximal β-adrenergic receptor signaling. Cellular Signalling, 38, 127-133. doi: 10.1016/j.cellsig.2017.07.006.

  • Verma, S., Garikipati, V., Krishnamurthy, P., Schumacher, S., Grisanti, L., Cimini, M., Cheng, Z., Khan, M., Yue, Y., Benedict, C., Truongcao, M., Rabinowitz, J., Goukassian, D., Tilley, D., Koch, W., & Kishore, R. (2017). Interleukin-10 inhibits bone marrow fibroblast progenitor cell-mediated cardiac fibrosis in pressure-overloaded myocardium. Circulation, 136(10), 940-953. doi: 10.1161/CIRCULATIONAHA.117.027889.

  • Grisanti, L., Guo, S., & Tilley, D. (2017). Cardiac GPCR-Mediated EGFR Transactivation: Impact and Therapeutic Implications. Journal of Cardiovascular Pharmacology, 70(1), 3-9. doi: 10.1097/FJC.0000000000000462.

  • Kolpakov, M., Tilley, D., & Sabri, A. (2017). Gα q Signaling in the Regulation of Autophagy and Heart Failure. Journal of Cardiovascular Pharmacology, 69(4), 212-214. doi: 10.1097/FJC.0000000000000471.

  • Tilley, D. & Sabri, A. (2017). DUSPs as critical regulators of cardiac hypertrophy. Clinical Science, 131(2), 155-158. doi: 10.1042/CS20160766.